Genetic characterization of novel oral polio vaccine Type 2 viruses during initial use phase under emergency use listing-worldwide, March-October 2021
File(s)mm7124a2-H.pdf (325.38 KB)
Published version
Author(s)
Type
Journal Article
Abstract
What is already known about this topic?
Sabin oral polio vaccine virus can revert to neurovirulence in populations with low immunity. A genetically stable novel type 2 oral poliovirus vaccine (nOPV2) was authorized for outbreak response use under a World Health Organization Emergency Use Listing.
What is added by this report?
Global nOPV2 genomic surveillance during March–October 2021 confirmed genetic stability of the primary attenuating site.
What are the implications for public health practice?
nOPV2 is used to respond to poliovirus outbreaks with comparatively low risk for generating new circulating strains. Given the background immunity, population dynamics, and scale of use, the consistent pattern of genetic characteristics of nOPV2 isolates is encouraging. nOPV2 surveillance should continue for the duration of the Emergency Use Listing.
Sabin oral polio vaccine virus can revert to neurovirulence in populations with low immunity. A genetically stable novel type 2 oral poliovirus vaccine (nOPV2) was authorized for outbreak response use under a World Health Organization Emergency Use Listing.
What is added by this report?
Global nOPV2 genomic surveillance during March–October 2021 confirmed genetic stability of the primary attenuating site.
What are the implications for public health practice?
nOPV2 is used to respond to poliovirus outbreaks with comparatively low risk for generating new circulating strains. Given the background immunity, population dynamics, and scale of use, the consistent pattern of genetic characteristics of nOPV2 isolates is encouraging. nOPV2 surveillance should continue for the duration of the Emergency Use Listing.
Date Issued
2022-06-17
Date Acceptance
2022-06-01
Citation
MMWR : Morbidity & Mortality Weekly Report, 2022, 71 (24), pp.786-790
ISSN
0149-2195
Publisher
Centers for Disease Control and Prevention
Start Page
786
End Page
790
Journal / Book Title
MMWR : Morbidity & Mortality Weekly Report
Volume
71
Issue
24
Copyright Statement
All material in the MMWR series is in the public domain and may be used and reprinted without special permission; citation as to source, however, is appreciated.
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000813446600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Life Sciences & Biomedicine
Public, Environmental & Occupational Health
Science & Technology
Publication Status
Published
Date Publish Online
2022-06-17